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Preface	  (max	  100	  words)	  
A	  plethora	  of	   groundbreaking	   studies	  have	  demonstrated	   the	   importance	  of	   chromatin-­‐associated	  
proteins	   and	   post-­‐translational	   modifications	   of	   histones,	   proteins	   and	   DNA	   (so-­‐called	   epigenetic	  
modifications)	  for	  transcriptional	  control	  and	  normal	  development.	  	  Disruption	  of	  epigenetic	  control	  
is	   a	   frequent	  event	   in	  disease,	   and	   the	   first	   epigenetic-­‐based	   therapies	   for	   cancer	   treatment	  have	  
been	  approved.	  	  A	  generation	  of	  new	  classes	  of	  potent	  and	  specific	  inhibitors	  for	  several	  chromatin-­‐
associated	   proteins	   have	   shown	   promise	   in	   pre-­‐clinical	   trials.	   	   Although	   the	   biology	   of	   epigenetic	  




Epigenetics	   is	   defined	   as	   heritable	   traits	   not	   linked	   to	   changes	   in	   the	  DNA	   sequence,	   however,	   in	  
more	  broad	  terms,	  epigenetics	   is	  used	  to	  describe	  the	  mechanisms	  by	  which	  chromatin-­‐associated	  
proteins	   and	   post-­‐translational	  modifications	   (PTMs)	   of	   histones	   regulate	   transcription.	   	  While	   all	  
cells	   within	   an	   organism	   contain	   the	   same	   DNA,	   epigenetic	   regulators	   and	   transcription	   factors	  
organize	   the	   genome	   into	   accessible	   and	   closed	   regions,	  which	   ensure	   the	   correct	   transcriptional	  
program	   in	  a	  given	  cell	   type.	   	  Thus,	  epigenetic	   regulation	   is	   important	   for	  maintaining	  cell	   identity	  
and	   is	   implicated	   in	  fundamental	  processes	  such	  as	  proliferation,	  development,	  differentiation	  and	  
genome	   integrity.	   	   Epigenetic	   gene	   regulation	   can	  be	  mediated	   via	  DNA	  methylation,	   nucleosome	  
remodelling,	   exchange	   of	   histone	   variants	   and	   PTMs	   of	   the	   histones	   (Box	   1).	   	   Histones	   can	   be	  
modified	  at	  specific	  amino	  acids	  with	  an	  increasingly	  diverse	  set	  of	  chemical	  modifications,	  such	  as	  
phosphorylation,	  acetylation	  or	  methylation,	  ubiquitylation	  or	  SUMOylation1,2.	   	  Research	  in	  the	  last	  
decade	  has	   led	   to	   a	  better	  understanding	  of	   the	   significance	  of	   these	  PTMs.	   	   This	   progress	  has	   in	  
particular	  been	  achieved	  through	  the	   identification	  of	  chromatin-­‐associated	  proteins	   that	  catalyse,	  
recognize	   and	   erase	   the	   specific	   modification	   (Box	   1),	   the	   generation	   of	   high	   affinity	   antibodies	  
specific	  for	  the	  post-­‐translational	  modification,	  genome-­‐wide	  location	  analysis	  and	  genetic	  studies.	  	  
	   	  Deregulation	  of	  epigenetic	  control	   is	  a	  common	  feature	  of	  a	  number	  of	  diseases	   including	  
brain	  disorders	  and	  cancer3.	   	  The	   involvement	  of	  DNA	  methylation	   in	  cancer	  has	  been	  appreciated	  
for	  a	  number	  of	  years,	  and	  the	  approval	  of	  the	  first	  drugs	  targeting	  DNA	  methylation	   is	  a	  hallmark	  
for	  epigenetic-­‐based	  therapies.	  	  The	  two	  approved	  drugs,	  azacitidine	  (5-­‐azacytidine)	  and	  decitabine	  
(5-­‐aza-­‐2’-­‐deoxycytidine),	   are	   nucleoside	   analogues	   and	   irreversible	   inhibitors	   of	   the	   DNA	  
methyltransferase	  enzymes,	  DNMT1	  and	  DNMT3.	  	  They	  are	  currently	  used	  as	  first-­‐line	  treatment	  of	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patients	  with	  myelodysplastic	  syndrome4,5.	   	  Shortly	  after	  the	  approval	  of	  the	  two	  DNA	  methylation	  
inhibitors,	   the	   two	   histone	   deacetylase	   (HDAC)	   inhibitors	   suberoylanilide	   hydroxamic	   acid	   (SAHA)	  
and	  Romidepsin	  (Depsipeptide,	  FK228)	  were	  approved	  for	  the	  treatment	  of	  refractory	  cutaneous	  T-­‐
cell	   lymphoma6,7.	   	   Although	   the	   introduction	   of	   these	   drugs	   in	   the	   clinic	   has	   been	   a	   tremendous	  
success	  for	  the	  field,	  a	  number	  of	  scientific	  challenges	  remain.	  	  Despite	  many	  years	  of	  research,	  we	  
do	  not	  understand	  exactly	  how	  and	  why	  these	  drugs	  work.	  	  For	  the	  HDAC	  inhibitors,	  acetylation	  is	  in	  
general	   increased	   following	   drug	   treatment,	   however,	   data	   demonstrating	   a	   correlation	   between	  
HDAC	   activity	   and	   therapeutic	   index	   is	   still	   lacking.	   	   Similarly,	   so	   far	   there	   is	   no	   established	   gene	  
expression	  signature	  or	  profile	  that	  can	  predict	  whether	  a	  patient	  will	  benefit	  from	  the	  use	  of	  HDAC	  
inhibitors.	  	  The	  picture	  is	  very	  similar	  for	  the	  DNMT	  inhibitors.	  	  Although	  these	  molecularly	  targeted	  
drugs	  have	  the	  potential	  of	   reverting	   the	  epigenetic	  modification	  and	  have	  been	  shown	  to	   lead	  to	  
global	  hypomethylation,	  we	  do	  not	  know	  the	  precise	  mechanism	  of	  action	  of	  these	  drugs.	  	  For	  both	  
classes	   of	   drug,	   the	   lack	   of	   reliable	   molecular	   biomarkers	   for	   predicting	   either	   clinical	   activity	   or	  
resistance	  is	  a	  serious	  drawback	  limiting	  the	  ability	  to	  achieve	  the	  vision	  of	  ‘personalized	  medicine’	  
and	   despite	   a	   large	   number	   of	   clinical	   trials,	   the	   use	   of	   the	   4	   drugs	   is	   so	   far	   limited	   to	   specific	  
haematological	  cancers.	  
	   The	   recent	  use	  of	  next-­‐generation	   sequencing	   technologies	  on	  DNA	   isolated	   from	  primary	  
tumours	   has	   revealed	   a	   high	   frequency	   of	   somatic	   mutations	   in	   genes	   coding	   for	   chromatin-­‐
associated	   proteins	   known	   to	   regulate	   DNA	   methylation	   patterns,	   histone	   PTMs	   and	   chromatin	  
remodelling	  (see	  Ref.	  8	  for	  a	  recent	  review).	   	  Strikingly,	  the	  discovery	  that	  patients	  with	  leukaemia	  
often	   have	  mutations	   in	   genes	   such	   as	   TET2,	   IDH1,	   IDH2	   and	  DNMT3A,	   which	   are	   all	   involved	   in	  
regulating	   DNA	   methylation	   patterns,	   might	   give	   insight	   into	   why	   leukaemia	   patients	   show	   a	  
significant	   response	   to	  DNA	  methylation	   inhibitors,	   and	   in	   addition	   could	   hold	   promise	   for	   future	  
patient	  stratification	  strategies.	   	   In	   fact,	   the	   lack	  of	  genetic	  data	   to	  support	   the	   role	  of	  chromatin-­‐
associated	   proteins	   in	   cancer	   has	   been	   a	   major	   obstacle	   for	   the	   development	   of	   patient	   specific	  
targeted	   therapies.	   	   This	   has	   dramatically	   changed	   with	   the	   recent	   findings	   that	   chromatin-­‐
associated	   proteins	   often	   show	   aberrant	   expression	   in	   cancer	   as	   a	   result	   of	   translocations	   and/or	  
genetic	  amplifications,	  and	  now	  also	  by	  the	  discovery	  that	  they	  carry	  specific	  somatic	  mutations.	  	  	  
In	   this	   review,	   we	   will	   focus	   on	   the	   recent	   advances	   in	   the	   scientific	   and	   pharmaceutical	  
communities	   to	   develop	   highly	   potent	   and	   specific	   inhibitors	   to	   chromatin-­‐associated	   proteins	  
(Table	   1).	   	   These	   represent	   several	   new	   classes	   of	   therapeutic	   targets	   and,	   as	   we	   will	   exemplify,	  
recent	   results	   have	   shown	   the	   feasibility	   of	   developing	   specific	   inhibitors	   to	   histone	  
methyltransferases,	   histone	   demethylases,	   and	   domains	   required	   for	   the	   binding	   of	   protein	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complexes	   to	   specific	  histone	  modifications.	   	   This	   is	  a	  very	  exciting	   time	   for	   the	   field	   in	  which	   the	  
combination	  of	   knowledge	   regarding	   the	   role	  of	   chromatin-­‐associated	  proteins	   in	  disease	  and	   the	  
development	   of	   potentially	   new	   classes	   of	   epigenetic	   drugs	   hopefully	   will	   lead	   to	   molecularly	  
targeted	  and	  less	  toxic	  therapies	  with	  a	  clear	  genetic	  marker(s)	  for	  patient	  stratification.	  	  
	  
Targeting	  Histone	  Methyltransferases	  
An	   association	   between	   histone	   hypermethylation,	   transcriptional	   regulation	   and	   the	   cancer	  
phenotype	   has	   spurred	   efforts	   to	   develop	   specific,	   small	   molecule	   inhibitors	   of	   the	  
methyltransferase	   enzymes	   involved	   in	   histone	   lysine	   and	   arginine	   methylation.	   	   The	   family	   of	  
histone	   methyltransferases	   (HMTs	   or	   more	   accurately,	   protein	   methyltransferases,	   PR/KMTs)	  
encompasses	   over	   sixty	   different	   proteins	   that	   sequentially	   transfer	   a	   methyl	   group	   from	   the	  
cofactor	   S-­‐adenosylmethionine	   (SAM)	   to	   the	   terminal	   amine	   of	   specific	   substrate	   lysine	   and/or	  
arginine	   residues.	   	   With	   the	   notable	   exception	   of	   DOT1L	   (see	   below),	   the	   catalytic	   transfer	   of	   a	  
methyl	  group	  from	  SAM	  occurs	  within	  a	  conserved	  SET	  domain,	  which	  accommodates	  the	  cofactor	  
and	   peptide	   substrates	   in	   a	   conformation	   conducive	   for	   an	   SN2	   transfer	   reaction	   generating	   S-­‐
adenosylhomocysteine	   (SAH)	  and	   the	  methylated	  histone	  side	  chain	  as	  products	   (Fig.	  1).	   	  Detailed	  
structural	  determinations	  of	  multiple	  SET	  domain	  containing	  HMTs	  have	  been	  carried	  out	  to	  support	  
this	   mechanistic	   rationale	   for	   the	   methyl	   transfer	   event	   and	   with	   a	   detailed	   analysis	   of	   binding	  
modes	  of	   cofactor	  and/or	  peptide	   substrates,	   to	  enable	   the	   rational	  design	  of	   selective	   inhibitors.	  	  
An	  understanding	  of	  exactly	  how	  the	  degree	  of	  histone	   lysine	  methylation	  modulates	  transcription	  
remains	   to	   be	   attained,	   but	   the	   need	   for	   the	   coordinated	   recruitment	   of	   methylation-­‐sensitive	  
proteins	   to	   transcriptional	   complexes	   offers	   one	   plausible	   hypothesis.	   Interestingly,	   the	  
methyltransferases	  have	  also	  been	  reported9-­‐11	  to	  act	  on	  various	  non-­‐histone	  protein	  substrates	  to	  
regulate	   their	   functions.	   	   However,	   the	   relative	   contributions	   of	   histone	   vs.	   non-­‐histone	   action	   of	  
HMTs	  are	  not	  well	  understood	  and	  continue	  to	  be	  an	  area	  of	  active	  investigation.	  	  	  
In	   the	  cancer	  context,	  undoubtedly	   the	  discovery	  of	  genetic	  alterations	   in	  HMTs	   in	  several	  
different	   tumour	   types12-­‐14	   has	   attracted	  much	   attention	   and	   provided	   additional	   support	   for	   the	  
importance	  of	   epigenetic	   deregulation	   in	   a	  disease	  widely	   considered	   to	  be	   genetically	   driven.	   	   In	  
some	  cases	   (e.g.	  EZH2	  below),	  heterozygous	  point	  mutations	   in	   the	  catalytic	  SET	  domain	   lead	  to	  a	  
gain	  of	   function	  of	   the	  wild	   type	  enzyme15,16	   favouring	   trimethylation	  and	   the	   silencing	  of	   tumour	  
suppressor	   genes	   and/or	   differentiation	   specific	   genes.	   	   Similarly,	   in	   other	   cancers	   (e.g.	   NSD2	   in	  
multiple	   myeloma),	   chromosomal	   translocations	   result	   in	   increased	   expression	   of	   the	  
methyltransferases	   again	   leading	   to	   aberrant	   transcription	   and	   proliferation17.	   Conversely,	   lysine	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methylation	  induced	  by	  the	  HMT	  DOT1L	  results	  in	  sustained	  expression	  of	  several	  genes	  required	  for	  
leukemogenesis.	   	   Therefore,	   small	  molecule	   inhibitors	   to	   for	   instance	  EZH2	  or	  DOT1L	   should	  have	  
the	  ability	   to	   reduce	  or	  eliminate	   the	   site-­‐specific	   lysine	  methylation	   introduced	  by	   the	  HMTs	  and	  
reverse	  the	  oncogenic	  state	  (see	  further	  below).	  	  
	  
DOT1L	  
Chromosomal	  translocations	  are	  relatively	  common	  in	  various	  hematopoietic	  malignancies	  and	  can	  
be	  associated	  with	  aggressive	  or	  poorly	  responsive	  disease.	  	  In	  leukaemia	  involving	  rearrangement	  of	  
the	  Mixed	  Lineage	  Leukemia	  (MLL)	  gene,	  translocation	  leads	  to	  fusions	  with	  more	  than	  50	  different	  
protein	  partners	  including	  ENL,	  ELL,	  AF4	  and	  AF9	  (Fig.	  2a)18.	  	  The	  resulting	  fusion	  complexes	  bind	  to	  
the	  HMT	  DOT1L,	  which	  specifically	  methylates	  the	  core	  histone	  residue	  histone	  H3	  lysine79	  (H3K79)	  
and	   contributes	   to	   transcriptional	   activation	   of	   HOXA10,	   MEIS1	   and	   other	   genes	   required	   for	  
leukaemia	   initiation19.	   	   DOT1L	   lacks	   the	   SET	   domain	   commonly	   present	   in	   other	   lysine	  
methyltransferases	   but	   nonetheless	   can	   readily	   catalyse	   the	   transfer	   of	   one,	   two	   or	   three	  methyl	  
groups	  to	  the	  ε-­‐NH2	  group	  of	  H3K79.	  	  In	  a	  critical	  paper	  from	  the	  Armstrong	  lab20,	  deletion	  of	  DOT1L	  
in	  MLL-­‐rearranged	   cell	   lines	   and	   subsequently	   in	   in	   vivo	  mouse	   studies	   directly	   demonstrated	   the	  
role	   of	   the	   enzyme	   not	   only	   in	   introducing	   the	  H3K79	  mark	   leading	   to	   a	   concomitant	   increase	   in	  
gene	  expression	  but	  also	  in	  the	  development	  of	  the	  leukaemia.	  
Given	   the	   significant	   role	   of	   DOT1L	   in	  MLL-­‐rearranged	   leukaemia,	   inhibitors	   of	   its	   H3K79	  
methyltransferase	  activity	  have	  been	  aggressively	  pursued	  as	  potential	  therapeutics.	   	  EPZ004777,	  a	  
SAM	  competitive	  pyrrolopyrimidine	  derivative	   (Fig.	   2b,	   1)	  was	  designed21	   to	  mimic	  both	   SAM	  and	  
the	   reaction	   product	   SAH	   whilst	   also	   taking	   advantage	   of	   potential	   hydrophobic	   interactions	  
available	   in	   the	   binding	   vicinity.	   	   The	   compound	   is	   an	   extremely	   potent	   and	   remarkably	   selective	  
SAM-­‐completive	   inhibitor	   of	   the	   enzyme.	   	   In	  MLL-­‐rearranged	   cell	   lines,	   EPZ004777	   reduces	   global	  
H3K79me2	   levels,	   blocks	   the	   expression	   of	   MLL-­‐fusion	   target	   genes	   and	   has	   antiproliferative	  
activity21.	   	  Consistent	  with	  a	  targeted	  mechanism	  of	  action,	  only	  cell	   lines	  with	  an	  MLL	  gene	  fusion	  
were	  sensitive	  to	  the	  DOT1L	  inhibitor	  whilst	  non-­‐rearranged	  lines	  remained	  unaffected.	  	  Regardless	  
of	   the	   measured	   parameter,	   the	   kinetics	   of	   cellular	   response	   to	   DOT1L	   inhibition	   (and	   other	  
epigenetic	  drugs	  reported	  so	  far)	  is	  strikingly	  distinct	  to	  the	  more	  rapid	  response	  usually	  seen	  within	  
a	   few	   hours	   with	   signal	   transduction	   modulators	   (kinase	   inhibitors)	   or	   non-­‐specific	  
chemotherapeutic	  drugs.	  	  Thus,	  the	  maximal	  effect	  on	  depletion	  of	  the	  methyl	  mark	  is	  typically	  seen	  
only	  after	  4-­‐5	  days	  of	  exposure	  to	  drug.	  	  Similarly,	  significant	  transcriptional	  changes	  occur	  after	  6-­‐8	  
days	   and	   >10	   days	   are	   required	   to	   observe	   an	   antiproliferative	   phenotype.	   	   Defining	   and	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understanding	  these	  distinctive	  characteristics	  have	  important	   implications	  for	  the	  development	  of	  
these	  agents	  since	  established	  measures	  of	  biomarker	  based	  pharmacodynamic	  and/or	  early	  clinical	  
response	   may	   be	   inappropriate.	   	   In	   addition,	   prolonged	   exposure	   to	   drug	   may	   be	   required	   for	  
efficacy	   further	  highlighting	   the	  need	   for	  a	   selective	  compound	  with	  presumably	   lower	  propensity	  
for	  undesirable	  off-­‐target	  effects.	  	  Encouragingly,	  in	  preclinical	  experiments,	  EPZ004777	  appeared	  to	  
be	  well	  tolerated	  when	  administered	  to	  mice	  at	  efficacious	  doses21.	  
Unfortunately,	  notwithstanding	  these	  attractive	  attributes,	  poor	  pharmacokinetics	  including	  
a	  short	  plasma	  half-­‐life	  requires	  EPZ004777	  to	  be	  administered	  as	  a	  seven	  day	  continuous	   infusion	  
using	   surgically	   implanted	   mini-­‐osmotic	   pumps.	   	   In	   a	   preclinical	   setting,	   such	   studies	   are	   readily	  
conducted	   but	   can	   pose	   significant	   challenges	   in	   clinical	   studies	   involving	   cancer	   patients.	   	   In	   an	  
attempt	  to	  address	  these	  shortcomings,	   further	  modifications	  of	   the	  pyrrolopyrimidine	  core	  of	   the	  
EPZ004777	   have	   been	   investigated22	   as	   an	   approach	   to	   designing	   second-­‐generation	   DOT1L	  
targeting	   drugs.	   	   For	   example,	   the	   Structural	   Genomics	   Consortium	   (SGC)	   has	   described	   bromo-­‐
deaza-­‐SAH	  (Fig.	  2b,	  2)	  as	  a	  convenient	  DOT1L	  inhibitor	  allowing	  for	  the	  generation	  of	  X-­‐ray	  co-­‐crystal	  
structures	   and	   hence	   rational	   design	   of	   novel	   analogues	   with	   improved	   properties23.	   	   The	   recent	  
initiation	  by	  Epizyme	  of	  clinical	  trials	  to	  determine	  the	  safety	  and	  efficacy	  of	  the	  DOT1L	  inhibitor	  EPZ-­‐
5676	   (Ref.	   24)	   in	   patients	   with	  MLL-­‐leukemia	   is	   highly	   significant	   and	   represents	   the	   first	   human	  
study	  of	  a	  ‘targeted’	  histone	  methyltransferase	  inhibitor.	  
	  
EZH2	  
Enhancer	   of	   Zeste	   Homolog	   2	   (EZH2)	   is	   the	   catalytic	   component	   of	   the	   multi	   protein	   polycomb	  
repressive	   complex	   2	   (PRC2)	   and	   acts	   as	   a	  HKMT	   at	  H3K27.	   	   Importantly,	   in	   cell	   free	   systems	   the	  
EZH2	   subunit	   is	   only	   catalytically	   competent	  when	   in	   a	   complex	  with	   at	   least	   two	   non-­‐enzymatic	  
partners	   (EED	   and	   SUZ12)	   and	   moreover	   in	   a	   physiologically	   relevant,	   intracellular	   context,	   the	  
complex	  is	  known	  to	  contain	  two	  additional	  proteins	  (AEBP2	  and	  RBBP4/7)	  (Fig.	  2c)25.	  	  
PRC2	   maintains	   the	   transcriptional	   repression	   of	   a	   large	   number	   of	   genes	   with	   key	  
regulatory	   roles	   in	   development	   and	   differentiation,	   and	   PRC2	   proteins	   are	   required	   for	   normal	  
embryonic	  development25.	   	  Pioneering	  studies	   from	  the	  Chinnaiyan	   lab	  have	  shown	  an	  association	  
between	   increased	   levels	  of	  both	  EZH2	  and	  H3K27me3	  and	  poor	  outcomes	   in	  metastatic	  prostate	  
cancer26.	   	   In	   addition,	   inactivating	   mutations	   in	   UTX,	   a	   H3K27	   demethylase27,28	   are	   also	   similarly	  
correlated	  suggesting	  a	  key	  role	  for	  H3K27	  hypermethylation	  in	  prostate	  cancer.	  	  Other	  studies	  have	  
revealed	  a	  similar	  relationship	  between	  elevated	  levels	  of	  EZH2	  with	  silencing	  of	  EZH2	  target	  genes	  
and	  poor	  prognosis	  in	  solid	  tumours	  including	  breast,	  kidney,	  and	  lung29-­‐32.	  	  More	  recently,	  somatic	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activating	  mutations	  in	  the	  SET	  domain	  of	  EZH2	  have	  been	  identified	  in	  follicular	  lymphoma	  (FL),	  and	  
diffuse	  large	  B	  cell	  lymphoma	  (DLBCL),	  leading	  to	  increased	  H3K27me3	  (Refs.	  33-­‐35).	  	  Taken	  together,	  
these	  findings	  suggest	  that	  misregulation	  of	  H3K27me3	  levels,	  through	  EZH2	  overexpression	  or	  point	  
mutations,	   silences	   target	   genes	   important	   in	   tumour	  growth	  and	   survival	   and	  make	  a	   compelling	  
case	   for	   targeting	   the	   enzyme	   therapeutically.	   	   Paradoxically	   however,	   inactivating	   mutations	   in	  
EZH2	   have	   also	   been	   reported	   in	   myelodysplastic	   syndrome	   (MDS)36	   raising	   the	   potential	   of	   a	  
tumour	  suppressor	  function	  for	  the	  protein.	  	  The	  role	  of	  EZH2	  and	  H3K27	  methylation	  in	  promoting	  
or	   inhibiting	   tumourigenesis	  and/or	  maintenance	  appears	   therefore	   to	  be	  context	  dependent	  and,	  
based	   on	   the	   potential	   for	   deleterious	   effects,	   suggests	   caution	   in	   developing	   chronically	  
administered	   therapeutic	   inhibitors.	   	   Despite	   these	   potential	   drawbacks,	   multiple	   pharmaceutical	  
and	   biotech	   company	   research	   groups	   have	   developed	   highly	   potent,	   selective,	   small	   molecule	  
inhibitors	   of	   EZH2	   (Refs.	   37-­‐39),	   and	   other	   investigators	   have	   pursued	   equally	   interesting	   natural	  
product-­‐based	  inhibitors40.	  
Medicinal	  chemistry	  design	  of	  HMT	  inhibitors	  has	  sought	  to	  take	  advantage	  of	  the	  intrinsic	  
affinity	   of	   EZH2	   for	   both	   S-­‐adenosyl-­‐L-­‐homocysteine	   (SAH,	   Ki	   =	   7.5	   uM)	   and	   lysine	   containing	  
substrate	  mimetics.	   	  Hybrid	  molecules	  such	  as	  shown	  in	  Fig.	  2d	  (3)	  containing	  discrete	  elements	  of	  
both	  recognition	  motifs	  are	  modest	  inhibitors	  and	  presumably	  act	  as	  classical	  bisubstrate	  inhibitors41.	  	  
However,	  the	  relatively	  low	  permeability	  of	  these	  highly	  charged	  compounds	  might	  limit	  their	  use	  in	  
cell-­‐based	  assays	  and	  in	  vivo.	  	  In	  contrast,	  despite	  being	  devoid	  of	  direct	  EZH2	  inhibitory	  activity,	  the	  
structurally	   related	   and	   widely	   used	   3-­‐deazaneplanocin	   (DZNep,	   Fig.	   2d,	   4)	   has	   been	   shown	   to	  
reactivate	   indirectly	   PRC2-­‐silenced	   genes	   in	   cancer	   cell	   lines	   by	   depleting	   PRC2	   subunits42.	  	  
Unfortunately,	  this	  activity	  does	  not	  allow	  for	  differentiation	  of	  selective	  catalytic	  inhibition	  of	  EZH2	  
from	  more	  global	  effects	  of	  depleting	  PRC2	  including	  loss	  of	  scaffolding	  functions,	  microRNA	  binding	  
sites	   etc.	   and,	   complicates	   interpretation	   of	   cellular	   phenotypes	   resulting	   from	   true	   inhibition	   of	  
H3K27	  methylation43.	   	  Ultimately,	   the	   use	   of	  DZNep	   in	   studies	   related	   to	   investigating	   the	   role	   of	  
EZH2	  inhibition	  in	  bioassays	  should	  be	  avoided.	  
High	   throughput	   screening	   of	   distinct	   compound	   libraries	   by	   various	   groups	   led	   to	   the	  
discovery	   of	   non-­‐SAM	  derived	   catalytic	   inhibitors	   of	   EZH2.	   	   Remarkably,	   all	   the	   screens	   identified	  
compounds	   with	   a	   pyridone	   amide	   motif	   indicating	   a	   critical	   molecular	   recognition	   role	   for	   the	  
functionality.	   	  Although	  these	  molecules	  do	  not	  resemble	  SAM,	  biochemically	  they	  are	  competitive	  
inhibitors	  of	  cofactor	  binding	  and	  various	  three	  dimensional	  homology	  models	  have	  been	  proposed	  
to	   rationalize	   how	   they	  may	  mimic	   the	   interactions	   of	   the	  natural	   substrate.	   	  Ultimately,	   detailed	  
structural	  studies	  will	  be	  needed	  to	  determine	  unequivocally	  if	  both	  occupy	  the	  same	  binding	  site	  in	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EZH2.	  	  Despite	  these	  uncertainties,	  extensive	  chemical	  modification	  of	  the	  screening	  hits	  to	  improve	  
affinity	  and	  pharmaceutical	  properties	  led	  to	  the	  discovery	  of	  analogues	  such	  as	  shown	  in	  Fig.	  2e37	  38	  
39,	  all	  highly	  potent,	  selective	  and	  bioavailable	   inhibitors	  of	  EZH2	  in	  biochemical	  and	  cellular	  assays	  
with	  in	  vivo	  antitumor	  activity	  in	  germinal	  cell	  diffuse	  large	  B	  cell	  lymphomas	  (DLBCL)	  with	  activating	  
EZH2	   mutations.	   	   Remarkably,	   these	   compounds	   show	   exquisite	   selectivity	   for	   EZH2	   inhibition	  
(>10,000-­‐fold)	  over	  most	  other	  methyl	  transferases	  and	  can	  distinguish	  from	  EZH1	  inhibition	  (~100-­‐
fold).	   	   One	   of	   these	   compounds	   (EPZ-­‐6438,	   E7438)	   has	   entered	   human	   clinical	   trials	   and	   several	  
others	   are	   likely	   to	   follow	   shortly	   allowing	   for	   an	   assessment	   of	   the	   therapeutic	   potential	   of	  
targeting	  EZH2	  in	  not	  only	  lymphoma	  but	  also	  in	  solid	  tumours	  with	  H3K27	  hypertrimethylation.	  	  In	  
this	  context,	  the	  recent	  report	  of	  the	  activity	  of	  an	  EZH2	  inhibitor	  in	  a	  preclinical	  model	  of	  paediatric	  
malignant	   rhabdoid	   cancer	   is	   notable.	   	   A	   subset	   of	   these	   tumours	  with	   inactivated	   SMARCB1	   are	  
thought	  to	  be	  dependent	  on	  the	  catalytic	  activity	  of	  EZH2	  and	  in	  xenograft	  models,	  were	  shown	  to	  
be	   sensitive	   to	   treatment	   with	   the	   potent	   and	   selective	   EZH2	   inhibitor,	   EPZ6438	   (Ref.	   44).	  	  
Interestingly	   and	   as	  mentioned	   above,	   other	   solid	   tumours	   (e.g.	   prostate,	   breast)	   have	   also	   been	  
associated	  with	  dramatic	  upregulation	  of	  EZH2	  expression	  but	  surprisingly,	  no	  convincing	  data	  has	  
emerged	   showing	  activity	  of	   catalytic	  EZH2	   inhibitors	   in	   these	   cancers.	   	  As	  with	  many	  other	  novel	  
potential	   therapeutics,	   the	   safety	   profile	   of	   EZH2	   inhibitors	   remains	   to	   be	   fully	   defined	   but	   initial	  
observations	   in	   prolonged	   animal	   studies	   suggest	   they	   are	   well	   tolerated	   with	   little	   or	   no	   overt	  
toxicity	  and,	  as	  mentioned	  above,	  E7438	  has	  been	  advanced	  to	  a	  phase	  1/2	  clinical	  trial	   in	  patients	  
with	  advanced	  solid	  tumors	  or	  with	  B-­‐cell	  lymphomas.	  
	  
Targeting	  Histone	  Demethylases	  
Previously,	   methylation	   was	   considered	   to	   constitute	   a	   permanent	   and	   irreversible	   histone	  
modification	   that	   defined	   epigenetic	   programs	   in	   concert	   with	   DNA	   methylation.	   However,	   the	  
discovery	  of,	  first	  the	  lysine-­‐specific	  demethylase	  1	  (LSD1,	  also	  known	  as	  KDM1A,	  AOF2,	  BHC110	  and	  
KIAA0601)	  and	  later	  the	  JmjC-­‐domain	  containing	  lysine	  demethylase	  family	  has	  completely	  changed	  
this	  view	  (for	   recent	   reviews,	   see	  45,46).	   	   LSD1	  and	   its	  close	   relative	  LSD2	   (aka	  KDM1B	  and	  AOF1)	  
belong	   to	   the	   superfamily	  of	   flavin	  adenine	  dinucleotide	   (FAD)-­‐dependent	  monooxidases	   (Fig.	  3a).	  	  
The	   two	   proteins	   can	   catalyse	   the	   demethylation	   of	   H3K4me2	   and	   H3K4me1,	   and	   LSD1	   has	   in	  
addition	  been	  shown	  to	  catalyse	  the	  demethylation	  of	  H3K9me2	  and	  H3K9me1	  as	  well	  as	  a	  number	  
of	  non-­‐histone	  proteins	  such	  as	  p53,	  DNMT1	  and	  E2F1.	  	  	  
	  
The	  JmjC-­‐domain	  family	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In	   contrast	   to	   the	   LSD	   demethylases,	   the	   JmjC-­‐domain	   containing	   demethylases	   can	   also	  
demethylate	   tri-­‐methylated	   lysines.	   	   This	   catalysis	   involves	   an	   oxidative	  mechanism	   requiring	   iron	  
and	  2-­‐oxoglutarate	  as	  co-­‐factors	  and	  most	  likely	  occurs	  through	  direct	  hydroxylation	  of	  the	  affected	  
methyl	   group	   (Fig.	   3b)45,46.	   	   There	   are	   30	  of	   these	   JmjC-­‐domain	   containing	  proteins	   in	   humans,	   of	  
which	  17	  have	  been	  shown	  to	  be	  active	  histone	  lysine	  demethylases.	  	  Several	  results	  have	  associated	  
the	  histone	  lysine	  demethylases	  with	  disease,	  in	  particular	  cancer	  and	  brain	  disorders.	  	  For	  instance,	  
members	  of	  the	  JMJD2/KDM4	  family,	  which	  can	  demethylate	  H3K9me3/me2	  and	  H3K36me3/me2,	  
have	  been	  found	  overexpressed	  in	  squamous	  cell	  carcinoma,	  breast	  cancer,	  and	  medulloblastoma47-­‐
49.	   	   Moreover	   members	   of	   the	   JARID1/KDM5	   family	   that	   demethylate	   H3K4me3/me2	   are	  
overexpressed	  in	  breast	  and	  bladder	  cancers50,51,	  and	  FBXL10/KDM2B,	  specific	  for	  H3K36me3/me2,	  
is	  overexpressed	  in	  leukaemia52.	  	  	  Somatic	  mutations	  and	  deletions	  have	  also	  been	  identified	  in	  the	  
JmjC-­‐domain	  containing	  demethylases,	  including	  the	  H3K27me3/me2	  demethylase	  UTX/KDM6A	  that	  
is	   found	   mutated	   in	   for	   instance	   multiple	   myeloma	   and	   renal	   cell	   carcinoma27,28,	   and	   in	  
JARID1C/KDM5C	  and	  PHF8	  in	  X-­‐linked	  mental	  retardation	  patients53,54.	   	  These	  mutations	  often	  lead	  
to	   loss	  of	  a	  functional	  demethylase,	  and	  since	  they	  may	  be	  responsible	  for	  the	  disease	  phenotype,	  
these	  observations	  could	  suggest	  that	  the	  corresponding	  histone	  methyl	  transferase	  is	  a	  good	  target	  
for	  drug	  development.	  	  	  
Although	   the	   understanding	   of	   the	   biological	   role	   of	   the	   histone	   demethylases	   in	   normal	  
development	   and	   disease	   is	   still	   relatively	   poor,	   the	   histone	   demethylases	   are	   considered	   as	  
attractive	  targets	  for	  drug	  development	  due	  to	  their	  association	  with	  disease	  and	  their	  well-­‐defined	  
catalytic	  mechanism.	  	  The	  use	  of	  structure-­‐guided	  design	  led	  recently	  to	  the	  first	  highly	  potent	  and	  
selective	   inhibitors	   to	   JmjC-­‐domain	  containing	  enzymes55.	   	  These	   inhibitors,	  which	  are	  competitive	  
with	  2-­‐oxoglutarate	  and	  non-­‐competitive	  with	  a	  peptide	  substrate	  are	  potent	  inhibitors	  with	  an	  IC50	  
in	   the	   nanomolar	   range,	   and	   were	   shown	   to	   be	   specific	   for	   the	   JMJD3/KDM6B	   and	   UTX/KDM6A	  
H3K27	  demethylases.	   	   JMJD3	  has	  previously	  been	  associated	  with	   inflammatory	   responses,	   and	   in	  
agreement	   with	   this	   the	   JMJD3/UTX	   inhibitor	   reduced	   proinflammatory	   cytokine	   production	   by	  
human	   primary	  macrophages55.	   	   In	   addition	   to	   showing	   the	   relevance	   for	   the	   catalytic	   activity	   of	  
JMJD3	   in	   this	   process,	   this	   study	   provided	   proof-­‐of-­‐concept	   for	   generating	   specific	   JmjC-­‐domain	  
inhibitors.	   	   Further	   proof-­‐of-­‐concept	   has	   been	   provided	   by	   the	   biotech	   company	   EpiTherapeutics,	  
which	  has	  developed	  highly	  potent	  inhibitors	  to	  the	  JARID1/KDM5	  family	  (Lars-­‐Ole	  Gerlach,	  personal	  
communication).	  	  These	  compounds	  show	  specific	  in	  vivo	  target	  engagement	  of	  JARID1B,	  increase	  in	  
H3K4me3	  levels	  in	  treated	  cells	  and	  reduced	  proliferation	  of	  cancer	  cells	  in	  a	  xenograft	  mouse	  model	  
[Lars-­‐Ole	   Gerlach,	   personal	   communication].	   	   These	   proof-­‐of-­‐concept	   studies	   provide	   support	   for	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that	   JmjC-­‐domain	   containing	   proteins	   can	   be	   targeted	   by	   specific	   compounds,	   which	   may	   have	  
therapeutic	  applications.	  	  
	  
LSD1	  
It	   is	   likely	  that	  the	  first	  small	  molecule	  inhibitors	  to	  histone	  demethylases	  that	  go	  into	  clinical	  trials	  
will	   target	   LSD1	   (Fig.	   3c)56.	   	   Several	   data	   have	   suggested	   that	   LSD1	   could	   be	   an	   interesting	  
therapeutic	  target	  in	  cancer,	  because	  of	  its	  high-­‐level	  expression	  in	  prostate	  cancer,	  undifferentiated	  
neuroblastoma,	   oestrogen-­‐negative	   breast	   cancer,	   bladder	   cancer	   and	   colorectal	   cancer57-­‐60.	  	  
Nevertheless,	  the	  recent	  demonstration	  that	  LSD1	  is	  required	  for	  the	  development	  and	  maintenance	  
of	  acute	  myeloid	  leukaemia	  (AML)	  has	  gained	  the	  most	  attention61,62.	  	  Specifically,	  both	  genetic	  and	  
pharmacological	   data	   have	   been	   provided	   in	   vitro	   and	   in	   animal	   models	   showing	   that	   LSD1	   is	  
required	  to	  sustain	  the	  expression	  of	  genes	  induced	  by	  the	  MLL-­‐AF9	  oncoprotein	  and	  therefore	  the	  
maintenance	  of	  the	  leukaemia	  stem	  cells	  (LSCs)61.	   	  The	  pharmacological	  results	   included	  the	  use	  of	  
the	   general	   monooxidase	   inhibitor	   tranylcypromine	   (TCP)62,	   and	   the	   TCP-­‐derivative	   [trans-­‐N-­‐((2-­‐
methoxypyridin-­‐3-­‐yl)methyl)-­‐2-­‐phenylcyclopropan-­‐1-­‐amine)]	   developed	   by	   the	   biotech	   company	  
Oryzon	   (Fig.	   3c)63,	  which	   is	  more	   specific	   and	   100-­‐fold	  more	   potent	   than	   TCP61.	   	   The	   inhibition	   of	  
LSD1	   in	   AML	   led	   to	   increased	   differentiation	   followed	   by	   apoptosis,	   and	   consistent	   with	   this	   an	  
increase	   in	  expression	  of	  differentiation	  markers	   (e.g.	  CD11b).	   	   The	   inhibition	  of	   LSD1	  activity	  was	  
not	   associated	   with	   a	   global	   increase	   in	   H3K4me2,	   however,	   some	   increase	   in	   H3K4me2	   was	  
observed	  on	  MLL-­‐AF9	  bound	  genes	  and	  genes	  involved	  in	  differentiation61,62.	  	  Taken	  together	  these	  
studies	   provide	   proof-­‐of-­‐concept	   for	   LSD1	   as	   a	   therapeutic	   target	   in	   leukaemia,	   however,	   the	  
mechanism	  by	  which	  LSD1	  contributes	  to	  leukaemia	  is	  not	  clear	  for	  several	  reasons.	  	  First,	  LSD1	  has	  
been	  found	  to	  be	  part	  of	  several	  chromatin	  complexes,	  including	  the	  neuronal	  silencer	  co-­‐repressor	  
of	   RE1-­‐silencing	   transcription	   factor	   (CoREST;	   also	   known	   as	   RCOR1)	   and	   the	   nucleosome	  
remodelling	  and	  histone	  deacetylase	  (NuRD)45	  (Fig.	  3d).	  	  These	  complexes	  are	  found	  throughout	  the	  
genome	  and	  have	  a	  pleotropic	  role	  in	  transcriptional	  regulation.	  	  Second,	  LSD1	  also	  binds	  throughout	  
the	  genome,	  especially	  at	  active	  promoters	  and	  enhancers64,65.	  	  Third,	  as	  mentioned	  above	  LSD1	  can	  
demethylate	   both	   H3K9me2/me1	   and	   H3K4me2/me1	   (Fig.	   3d).	   	   H3K9me2	   is	   normally	   found	  
associated	   with	   repressed	   chromatin	   and	   transcriptional	   silencing,	   whereas	   H3K4me2/me1	   is	  
associated	  with	  active	  promoters	  and	  enhancers.	  	  Inhibition	  of	  LSD1	  activity	  in	  AML	  did	  not	  lead	  to	  
any	  change	  in	  H3K9me2,	  whereas	  an	  increase	  of	  H3K4me2	  was	  observed	  on	  MLL-­‐AF9	  target	  genes61	  
and	   CD11b62.	   	   These	   observations	   raise	   several	   questions.	   	   First,	   if	   LSD1	   is	   bound	   throughout	   the	  
genome,	   why	   does	   the	   inhibition	   of	   LSD1	   lead	   to	   the	   selective	   increase	   of	   H3K4me2	   on	   specific	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promoters?	   	   Second,	   the	   expression	   of	   MLL-­‐AF9	   target	   genes	   is	   decreased	   in	   response	   to	   LSD1	  
inhibition,	  while	  H3K4me2	  is	  increased.	  	  This	  is	  counterintuitive,	  because	  an	  increase	  in	  H3K4me2	  is	  
normally	  associated	  with	  increased	  expression	  of	  a	  gene,	  as	  is	  the	  case	  for	  CD11b.	  	  Therefore,	  what	  
is	   the	   mechanism	   leading	   to	   the	   decreased	   expression	   of	   MLL-­‐AF9	   target	   genes,	   and	   how	   does	  
inhibition	  of	  LSD1	  lead	  to	  differentiation	  and	  apoptosis?	  	  
	   Despite	   the	   lack	   of	   precise	  mechanistic	   insights	   into	   the	   how	   LSD1	   inhibition	   can	   lead	   to	  
inhibition	  of	   leukaemia	  and	  prolonged	  survival	  of	  mice,	   the	  LSD1	   inhibitors	  appear	  very	  promising.	  	  
Oryzon	  Genomics	  recently	  reported	  on	  the	  further	  development	  of	  a	  clinical	  compound,	  ORY-­‐1001,	  
which	  is	  more	  than	  1000x	  more	  potent	  than	  TCP	  and	  highly	  selective	  over	  related	  enzymes,	  including	  
LSD2	  (Ref.	  66).	   	  The	  structure	  of	  ORY-­‐1001	  has	  not	  been	  revealed;	  however,	   it	  has	  been	  shown	  to	  
reduce	   leukaemic	   stem	   cell	   potential,	   colony	   formation,	   and	   to	   induce	   differentiation	  of	   AML	   cell	  
lines	   at	   sub-­‐nanomolar	   concentrations63.	   	  Moreover,	  ORY-­‐1001	   leads	   to	   the	   time/dose	  dependent	  
increase	   of	   H3K4me2	   at	   LSD1	   target	   genes	   (e.g.	   CD11b)	   and	   induction	   of	   differentiation	  markers	  
(Tamara	  Maes,	  personal	  communication).	  	  Oryzon	  Genomics	  expects	  to	  take	  ORY-­‐1001	  into	  phase	  I	  
clinical	  trials	  later	  this	  year.	  	  
	   Interestingly,	   the	  potential	   use	   of	   LSD1	   inhibitors	   is	   not	   limited	   to	   oncological	   disease.	   	   In	  
fact,	  the	  weak	  LSD1	  inhibitor	  TCP	  has	  been	  used	  as	  a	  non-­‐selective	  monoamine	  oxidase	  inhibitor	  for	  
the	  treatment	  of	  depression67,	  and	  since	  aberrant	  activity	  of	  the	  REST-­‐CoREST-­‐LSD	  complex	  has	  been	  
implicated	  in	  Huntington’s	  disease68	  and	  LSD1	  in	  Herpes	  infection69	  the	  LSD1	  inhibitors	  may	  also	  find	  
use	  for	  these	  indications.	  
	  
Targeting	  Bromodomains	  
Bromodomains	   constitute	   a	   small	   family	   of	   proteins	   that	   recognize	   and	   bind	   to	   acetylated	   lysine	  
residues	   on	   histone	   tails	   (Fig.	   4a).	   	   Acting	   both	   as	   a	   scaffold	   for	   the	   assembly	   of	   larger,	   multi-­‐
component	   macromolecular	   complexes	   regulating	   chromatin	   accessibility	   as	   well	   as	   for	   the	  
recruitment	   of	   key	   transcriptional	   proteins	   such	   as	   RNA	   polymerase,	   bromodomain-­‐containing	  
proteins	  are	  considered	  ‘readers’	  of	  the	  histone	  code.	  	  The	  human	  genome	  encodes	  a	  total	  of	  over	  
fifty	   bromodomain	   (BRD)	   proteins,	   which	   can	   be	   phylogenetically	   segregated	   in	   to	   eight	   sub-­‐
families70.	   	   Embryonic	   lethality	   upon	   genetic	   knock	   down	   of	   BRDs71	   underscores	   the	   primary	  
importance	  of	  the	  proteins	  in	  basic	  cell	  function	  but	  has	  also	  served	  to	  limit	  a	  better	  understanding	  
of	   their	   role	   in	  normal	  and	  disease	  physiology.	   	  Structurally,	   the	  BRDs	  are	  made	  up	  of	  a	  bundle	  of	  
four	   alpha	   helices	   joined	   by	   two	   closely	   interacting	   but	   sequence	   variable	   loops	   that	   form	   an	  
invaginated,	  largely	  hydrophobic	  pocket	  for	  binding	  to	  the	  acetylated	  lysine	  ligand70.	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The	   current	   intense	   interest	   in	   therapeutically	   targeting	   various	   BRDs	   originated	   in	   the	  
demonstration	  by	  GlaxoSmithKline	   (GSK),	   SGC	  and	  Bradner	   labs	   that	   the	  bromodomain	  and	  extra-­‐
terminal	   (BET)	   sub-­‐family	   (Brd2,	   Brd3,	   Brd4	   and	   BrdT)	   could	   be	   targeted	   by	   small	   molecule	  
antagonists72,73.	  	  By	  directly	  binding	  to	  the	  BET	  proteins,	  such	  compounds	  prevent	  the	  interaction	  of	  
the	   reader	   module	   to	   the	   acetylated	   histone	   thereby	   preventing	   assembly	   of	   an	   active	   gene	  
transcriptional	  complex	  (Fig.	  4a).	  	  The	  ability	  to	  disrupt	  these	  protein-­‐protein	  interactions	  with	  drug-­‐
like	  compounds	   is	  remarkable	  and	  has	  been	  shown	  in	  multiple	  structural	  studies67	  to	  be	  related	  to	  
the	   presence	   of	   well	   defined,	   deep	   acetyl	   lysine	   binding	   pockets	   within	   the	   BET	   proteins.	   	   By	  
applying	   cell	   based	   high	   throughput	   screening	   of	   compound	   libraries	   combined	   with	   elegant	  
chemoproteomics	   and	   a	   battery	   of	   structural	   and	   biophysical	   assays,	   GSK	   developed	   compounds	  
able	  to	  inhibit	  all	  four	  BET	  proteins	  but	  with	  good	  selectivity	  over	  other	  BRDs.	  	  Similarly,	  SGC	  working	  
with	  the	  Bradner	  lab	  developed	  the	  widely	  used	  JQ1	  (Fig.	  4b),	  originating	  from	  a	  patent	  application	  
by	   Mitsubishi-­‐Tanabe74.	   	   Critically,	   the	   free	   availability	   of	   these	   compounds	   to	   the	   research	  
community	  has	  dramatically	  accelerated	  understanding	  of	  the	  primary	  mechanism	  of	  transcriptional	  
regulation	  and	  wider	  chromatin	  biology.	  	  Indeed,	  the	  realization	  that	  the	  pharmacological	  effects	  of	  
BET-­‐inhibition	   could	   potentially	   be	   applied	   to	   ameliorate	   diverse	   disease	   phenotypes	   has	   spurred	  
further	  rounds	  of	  compound	  discovery	  in	  pharmaceutical	  companies.	  
Early	  evidence	  for	  the	  potential	  involvement	  of	  BET	  proteins	  in	  cancer	  was	  the	  observation	  
that	  overexpression	  of	  Brd2	  in	   lymphocytes	   induced	  B-­‐cell	   lymphomas.	   	  Subsequently,	  French	  et	  al	  
reported	   chromosomal	   translocation	   of	   the	   Brd4	   gene	   with	   the	   NUT	   protein	   was	   the	   driver	   for	  
proliferation	  in	  the	  rare	  but	  lethal	  malignancy,	  NUT-­‐midline	  carcinoma	  (NMC)75.	  	  Further,	  reversal	  of	  
the	  tumour	  phenotype	  with	  BET	  inhibition	  provided	  support	  not	  only	  for	  the	  underlying	  mechanism	  
but	   also	   illustrated	   the	   therapeutic	   potential	   of	   BET	   antagonism.	   	   Based	   on	   this	   data,	   a	   phase	   I	  
clinical	  study	  of	  the	  GSK	  BET	  inhibitor	  IBET762	  (Fig.	  4b),	  in	  NMC	  was	  initiated	  in	  March	  2012.	  
Investigation	   of	   the	   anti-­‐proliferative	   activity	   of	   BET	   inhibitors	   in	   models	   of	   hematologic	  
cancer,	   including	   AML,	   Burkitt’s	   lymphoma,	   multiple	   myeloma	   and	   B-­‐cell	   acute	   lymphoblastic	  
leukaemia	  has	  revealed	  perhaps	  the	  most	  exciting	  facet	  of	  BRD	  biology76,77.	   	   In	  these	  malignancies,	  
BET	  inhibitors	  such	  as	  JQ1	  and	  the	  more	  highly	  bioavailable	  IBET151	  (Fig.	  4b)	  directly	  silenced	  MYC	  
expression	  via	  disruption	  of	  BET	  protein	  binding	  at	  the	  MYC	   locus.	  	  Since	  the	  various	  MYC-­‐isoforms	  
are	  known	  to	  be	  critical	  regulators	  of	  cell	  proliferation	  and	  survival	  and	  MYC	   is	  a	  potent	  oncogene	  
overexpressed	  in	  many	  cancers,	  BRD	  antagonism	  offers,	  for	  the	  first	  time,	  an	  opportunity	  generally	  
to	   target	   MYC-­‐driven	   oncogenicity.	   	   Intriguingly,	   however,	   recent	   reports	   have	   shown	   critical	  
subtleties	   in	   the	   mechanism	   of	   BET	   inhibitor	   modulation	   of	   MYC78.	   	   Whereas	   in	   haematological	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cancers,	  BET	  regulates	  c-­‐MYC,	   in	  neuroblastoma,	  BET	   inhibitor	  effects	  appear	  to	  be	  manifested	  via	  
silencing	  of	  N-­‐MYC,	  presumably	  by	  the	  same	  or	  at	  least	  a	  similar	  mechanism.	  	  These	  results	  suggest	  
potential	   for	   a	   broader	   spectrum	   of	   activity	   for	   BET	   inhibitors	   beyond	   NMC	   and	   haematological	  
malignancies	   and	   ongoing	   clinical	   studies	   with	   IBET762	   now	   include	   other	   solid	   tumours	   such	   as	  
MYCN-­‐amplified	   lung	   and	   colorectal	   cancers.	   	   The	   question	   of	   a	   therapeutic	   window	   for	   BET	  
inhibitors	   in	   a	   clinical	   setting	   remains	   to	   be	   answered	   but	   presumably	   data	   from	   animal	   toxicity	  
studies	  did	  not	  preclude	  advancing	  these	  compounds	  to	  human	  trials.	  
Outside	   of	   cancer,	   BET	   inhibition	   has	   shown	   striking	   effects	   in	   a	   range	   of	   inflammatory	  
disease	   models	   suggestive	   of	   a	   central	   role	   in	   lymphocyte	   lineage	   aetiology.	   	   Interestingly,	   BET	  
inhibition	  with	  IBET762	  attenuated	  only	  secondary	  response	  genes	  in	  macrophages	  with	  no	  effect	  on	  
the	  primary	  response	  elements72.	  	  The	  ability	  to	  modulate	  selectively	  the	  expression	  of	  gene	  subsets	  
is	  of	  significance	  and	  raises	  the	  possibility	  of	   further	  fine-­‐tuning	  the	   level	  of	  transcriptional	  activity	  
with	   selective	   inhibitors	   of	   other	   BRDs,	   which	   could	   translate	   to	   clinical	   benefit(s)	   with	   fewer	  
undesirable	  side	  effects.	   	   In	  mouse	  models	  of	  sepsis,	  pretreatment	  with	  a	  BET	  inhibitor	  suppressed	  
cytokine	   expression	   and	   protected	   the	   animals	   from	   lethal	   LPS	   challenge.	   	   In	   a	   noteworthy	  
demonstration	   of	   activity,	   administration	   of	   the	   inhibitor	   even	   after	   allergen	   challenge	   led	   to	  
survival69.	   Evidence	  of	   the	   function	  of	   other	  BRDs	   (SP110,	   SP140,	   SMARCA4)	   in	   immune-­‐mediated	  
diseases	  driven	  by	  loss	  of	  memory	  T	  and	  B-­‐cells	  is	  emerging	  and	  limited	  to	  tantalizing	  association	  of	  
BRD	  expression	  and	  disease	  phenotype.	   	   It	   is	  too	  early	  to	  say	  whether	  small	  molecule	   inhibitors	  of	  
other	   BRDs	   or	  methyl-­‐lysine	   readers	   can	   be	   successfully	   identified,	   but	   some	   promising	   advances	  
have	   recently	   been	  made	  with	  BAZ2B	  and	   chromodomain	  proteins	   associated	  with	  brain	   tumours	  
(Table	   1).	   The	   development	   and	   availability	   of	   additional	   specific	   small	   molecule	   probes	   will	   be	  
needed	  help	  delineate	  the	  biology	  of	  these	  proteins.	  
	  
Conclusions	  and	  perspectives	  
This	  is	  a	  very	  exciting	  and	  fruitful	  time	  for	  the	  “epigenetics	  field”,	  illustrated	  with	  recent	  discoveries	  
of	  new	  classes	  of	  enzymes,	  insights	  into	  the	  biological	  role	  of	  chromatin-­‐associated	  proteins,	  findings	  
showing	  that	  somatic	  mutations	  in	  genes	  coding	  for	  chromatin-­‐associated	  proteins	  are	  very	  frequent	  
in	  cancer,	  and	  the	  development	  of	  highly	  potent	  and	  specific	  small	  molecule	  inhibitors	  to	  chromatin-­‐
associated	   proteins	   that	   show	   great	   promise	   in	   pre-­‐clinical	   trials.	   	   Until	   recently,	   it	  was	   uncertain	  
whether	   it	  would	  be	  technically	   feasible	   to	  generate	  specific	  and	  potent	   inhibitors	   to	   the	  different	  
classes	  of	  readers,	  writers	  and	  erasers	  of	  the	  histone	  code.	  	  However,	  as	  discussed	  in	  this	  review,	  this	  
indeed	  has	  been	  possible	  for	  very	  diverse	  enzymatic	  classes,	  such	  as	  the	  histone	  methyl	  transferases,	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the	   two	   different	   subclasses	   of	   histone	   demethylases,	   and	   for	   the	   non-­‐enzymatic	   bromodomain	  
containing	   proteins.	   	   These	   inhibitors	   are	   undergoing	   or	   will	   shortly	   enter	   human	   phase	   I	   clinical	  
trials	   for	   a	   variety	   of	   oncology	   indications	   albeit	   initially	   in	   rare	   tumour	   types	   or	   hematopoietic	  
malignancies.	  
A	  major	  challenge	  for	  a	  potential	  expansion	  of	  the	  inhibitors	  to	  other	  tumour	  types	  will	  be	  a	  
better	  understanding	  of	  the	  mechanism	  of	  action	  of	  the	  drugs,	  and	  therefore	  of	  the	  biology	  of	  the	  
target	  protein.	  	  The	  ongoing	  phase	  I	  clinical	  trials	  have	  all	  been	  designed	  based	  on	  genetic	  evidence	  
for	  a	  role	  of	  the	  targeted	  protein	  in	  the	  disease	  (DOT1L	  in	  AML,	  EZH2	  in	  DLBCL,	  LSD1	  in	  AML	  and	  IBET	  
in	  NUT-­‐midline	  carcinoma).	   	  Such	  strong	  genetic	  evidence	  does	  not	  currently	  exist	   in	  other	  tumour	  
types,	  however	   the	  effect	  of	   the	   specific	   inhibitors	  on	   large,	   “omically”	  well-­‐characterized	  cell	   line	  
panels	   will	   hopefully	   help	   to	   identify	   specific	   genetic	   alterations	   that	   lead	   to	   drug	   sensitivity.	  	  
Nonetheless,	   even	   this	   approach	   is	   unlikely	   to	   be	   straightforward	   because	   most	   chromatin-­‐
associated	  proteins	  are	  present	  in	  several	  different	  multi-­‐component	  complexes	  that	  are	  associated	  
with	   several	   thousand	   genes	   and	   loci	   throughout	   the	   genome.	   	   The	   biology	   is	   therefore	   complex,	  
and	   depending	   on	   the	   tissue	   and	   the	   underlying	   genetic	   landscape	   of	   the	   cell,	   the	   chromatin-­‐
associated	   protein	   could	   act	   as	   an	   oncogene	   in	   one	   setting	   but	   be	   a	   tumour	   suppressor	   in	   other	  
circumstances.	  	  This	  is	  for	  instance	  illustrated	  by	  EZH2,	  in	  which	  gain-­‐of-­‐function	  mutations	  promote	  
lymphoid	   transformation16,33,37,79,	   and	   loss-­‐of-­‐function	   mutations	   promote	   MDS	   and	   T-­‐ALL36,80-­‐83.	  	  
Similarly,	  somatic	  mutations	  of	  lysine	  27	  of	  H3.3	  found	  in	  paediatric	  glioblastoma	  have	  been	  shown	  
to	   inhibit	   EZH2	   activity84.	   	   The	   dual	   roles	   of	   EZH2	   and	   H3K27	   methylation	   might	   also	   reflect	   the	  
biological	  role	  of	  EZH2	  and	  the	  PRC2	  complex.	   	   In	  contrast	  to	  signalling	  pathways	  and	  transcription	  
factors,	   chromatin-­‐associated	   proteins	   and	   epigenetic	   regulation	   do	   not	   appear	   to	   be	   decisive	   for	  
lineage	  choice	  during	  differentiation.	   	   Instead	  these	  proteins	  are	  present	   in	   the	  genome	  to	  ensure	  
transcriptional	  patterns	  and	  cell	   identity.	   	   In	  other	  words,	   the	  chromatin-­‐associated	  proteins	  often	  
fine-­‐tune	  transcriptional	  patterns,	  and	  the	  genes	  regulated	  by	  the	  proteins	  can	  both	  be	  oncogenes	  
and	  tumour	  suppressor	  genes.	   	  These	  functions	  of	  the	  chromatin-­‐associated	  proteins	  do	  not	  mean	  
that	   inhibitors	   to	   these	   proteins	   will	   not	   have	   clinical	   benefit,	   but	   highlights	   the	   difficulty	   in	  
identifying	   biomarkers	   predictive	   of	   tumour	   sensitivity.	   	   This	   is	   again	   illustrated	   by	   the	   EZH2	  
inhibitors,	  where	   the	   levels	   of	   EZH2	   in	   a	   tumour	   cell	   line	  do	  not	  predict	  whether	   the	   cell	   line	  will	  
respond	  to	  the	   inhibitor,	  however,	  a	  weak	  correlation	  exists	  between	  the	  ability	  of	  EZH2	  inhibitors	  
(IC50	  values)	  to	  decrease	  H3K27me3	  levels	  in	  DLBCL	  and	  inhibition	  of	  cell	  growth37.	  	  	  
The	   generation	   of	   small	   molecule	   inhibitors	   to	   different	   classes	   of	   chromatin-­‐associated	  
proteins	  has	  increased	  not	  only	  confidence	  on	  the	  druggability	  of	  many	  epigenetic	  modulators,	  but	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has	  also	  provided	  strong	  insights	  into	  the	  rational	  design	  of	  new	  compounds	  with	  higher	  affinity	  and	  
specificity.	  	  The	  hope	  is	  that	  this	  knowledge	  can	  be	  translated	  to	  the	  generation	  of	  specific	  inhibitors	  
to	  the	  many	  other	  chromatin-­‐associated	  proteins	  involved	  in	  cancer.	  	  Minimally,	  such	  inhibitors	  will	  
be	   useful	   as	   research	   compounds	   to	   understand	   the	   biological	   function	   of	   novel	   chromatin-­‐
associated	  proteins	  but	  could	  eventually	  also	  allow	  for	  the	  identification	  and	  therapeutic	  targeting	  of	  
other	   pathways	   important	   for	   the	   cancer	   phenotype.	   	   Increasingly,	   it	   is	   becoming	   evident	   that	  
effective,	   long	   term	   responses	   to	   anti-­‐cancer	   therapies	   require	   suppression	   of	   two	   or	   more	  
oncogenic	   pathways	   and	   this	   is	   likely	   to	   be	   the	   case	   for	   epigenetic	   therapies	   as	   well.	   	   However,	  
modulation	   of	   the	   cancer	   epigenome	   with	   specific	   inhibitors	   may	   offer	   unique	   opportunities	   to	  
discover	   effective	   combination	   therapies	   based	   on	   the	   potential	   directly	   to	   alter	   acquired	  
transcriptional	  resistance	  mechanisms.	  	  Indeed,	  a	  recent	  report85	  demonstrating	  reversal	  of	  platinum	  
resistance	  with	  HDAC	  inhibition	  in	  ovarian	  cancer	  highlights	  such	  opportunities.	  	  Undoubtedly,	  other	  
rational	   combinations	   remain	   to	   be	   identified	   and	   the	   challenge	   will	   be	   to	   understand	   the	  
fundamental	  cellular	  alterations	   induced	  by	  epigenetic	  modulators	  and	  to	  develop	  complementary	  
agents	   that	   synergize	  most	   effectively.	   	   Along	   these	   lines,	   the	   resurgence	   and	   current	   success	   of	  
immunotherapeutic	   approaches	   to	   cancer	   treatment	   also	   offers	   opportunities	   for	   epigenetically	  
targeted	  therapeutics.	   	   In	  principle,	   it	  may	  be	  possible	  to	   induce	  cell	   surface	  expression	  of	   tumour	  
specific	  antigens	  allowing	  for	  more	  effective	  and	  sustained	  immune	  responses	  to	  tumours.	   	  Finally,	  
the	   ability	   to	   silence	   critical	   oncogenes	   such	   as	  MYC	   and	   BCL2	   with	   bromodomain	   inhibitors	   has	  
been	   remarkable	   and	   unpredicted.	   Inactivation	   of	   these	   master	   oncogenic	   proteins	   with	   small	  
molecules	  has	  been	   the	  Holy	  Grail	   for	  anti-­‐cancer	  approaches	   for	  many	  years.	   	  Yet	  even	  here,	   the	  
lack	  of	  a	  detailed	  mechanistic	  understanding	  of	  how	  the	  BET	   inhibitors	  work	  has	   led	  to	  an	  empiric	  
approach	  to	  determine	  how	  best	  to	  deploy	  these	  agents	  in	  the	  clinic.	  	  Despite	  these	  limitations,	  it	  is	  
important	  to	  remember	  we	  are	  nonetheless	  on	  the	  verge	  of	  advancing	  novel	  molecules	  with	  novel	  
biology	  to	  human	  studies	  with	  at	  least	  some	  molecular	  or	  pathway	  basis	  for	  selecting	  patients	  most	  
likely	  to	  benefit	  from	  these	  agents.	  	  Data	  from	  these	  studies	  will	  ultimately	  determine	  whether	  these	  
novel	  epigenetic	   therapies	  will	   add	  meaningfully	   to	   the	  armamentarium	  of	   the	  physicians,	  but	   the	  
signs	   are	   promising.
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Table	  1	  List	  of	  small	  molecule	  inhibitors	  to	  chromatin	  associated	  proteins	  
	  
Chromatin	  binding	  protein	   Compound	   Reference	  
Histone	  methyl	  transferases	  	   	   	  
DOT1L	   EPZ004777	   21	  
	   EPZ-­‐5676	   24	  
	   SGC0946	   86	  
EZH2	   GSK126	   37	  
	   GSK343	   87	  88	  
	   EPZ-­‐005687	   38	  
	   EPZ-­‐6438	   44	  
	   EI1	   39	  
	   UNC1999	   89	  
G9A	   BIX01294	   90	  
	   UNC0321	   91	  
	   UNC0638	   92	  
	   UNC0642	   88	  
	   BRD4770	   93	  
PRMT3	   14u	   94	  
PRMT4	  (CARM1)	   17b	  (BMS)	   95,96	  
	   MethylGene	   97	  
Histone	  demethylases	   	   	  
LSD1	   Tranylcypromine	   62	  
	   ORY-­‐1001	   63	  
JMJD3	   GSK-­‐J1	   55	  
Bromodomains	   	   	  
BET	   JQ1	   73	  
	   IBET762	   72	  
	   IBET151	   76,98	  
	   PFI-­‐1	   99	  
BAZ2B	   GSK2801	   88	  
Chromodomains	   	   	  
L3MBTL1	   	   100	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  in	  vitro	  and	  in	  vivo	  activity	  vs.	  EZH2	  
mutant	  lymphomas.	  
#44.	   	   Reports	   activity	   of	   EZH2	   inhibitors	   in	   solid	   tumours	   suggesting	   potential	   for	   clinical	   benefit	  
beyond	  haematological	  malignancies.	  
#55.	   Describes	   the	   discovery,	   structural	   biology	   and	   activity	   of	   potent	   and	   selective	   Jumonji	  
demethylase	  inhibitors.	  
#61,	  62.	   	  Highlight	  the	  role	  of	  LSD1	   in	  AML	  and	  the	  potential	   for	   inhibitors	  to	  synergize	  with	  ATRA	  
therapy.	  
#72,	   73,	   76,	   77.	   	   Outstanding	   studies	   showing	   demonstrating	   the	   feasibility	   of	   inhibiting	  
bromodomain	  proteins	  in	  inflammation	  and	  tumorigenesis.	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Figure	  Legends	  	  
Figure	   1	  Mechanism	   of	   lysine	  methylation	   catalysed	   by	   histone	   lysine	  methyltransferases.	   	   The	  
lysine	   amino	   group	   of	   the	   substrate	   histone	   polypeptide	   engages	   in	   an	   SN2	   reaction	   with	   the	  
activated	   co-­‐factor	   S-­‐adenosylmethionine	   (SAM)	   resulting	   in	   the	   formation	   of	   an	   N-­‐methylated	  
lysine	  and	  S-­‐adenosylhomocysteine	  (SAH).	  	  
	  
Figure	  2	  Histone	  methyltransferases	  and	  inhibitors	  to	  DOT1L	  and	  EZH2.	  	  a,	  	  DOT1L	  catalyses	  H3K79	  
methylation	  of	  nucleosomes	  associated	  with	  actively	  transcribed	  genes.	  	  It	  is	  recruited	  by	  MLL-­‐fusion	  
proteins	  (here	  exemplified	  by	  MLL-­‐AF10)	  to	  MLL-­‐target	  genes,	  and	  is	  required	  for	  leukaemia	  induced	  
by	  MLL-­‐fusion	  proteins.	  b,	   	  Specific	   inhibitors	  to	  DOT1L:	  EPZ004777	  (1,	  Ref.	  21)	  and	  Br-­‐SAH	  (2,	  Ref.	  
22).	  	  c,	  	  PRC2	  catalyses	  di-­‐	  and	  trimethylation	  of	  H3K27	  to	  maintain	  transcription	  repression	  of	  target	  
genes.	   	   These	   target	   genes	   are	   often	   associated	   H3K4me3	   as	   well,	   a	   mark	   of	   CpG-­‐islands	   and	  
transcription	  start	  sites.	  	  d,	  	  Reported	  EZH2	  inhibitors:	  3	  (Ref.	  41),	  DZNep	  (4,	  Ref.	  42),	  GSK126	  	  (5,	  Ref.	  
37),	  EPZ7438	  (6,	  Ref.	  38)	  and	  EI1	  (7,	  Ref.	  39).	  	  
	  
Figure	  3	  Histone	  demethylases	  and	  inhibitors	  to	  LSD1.	  	  a,	  	  Reaction	  mechanism	  for	  FAD-­‐dependent	  
LSD1	  and	  LSD2	  (modified	  from	  Ref.	  45).	  	  b,	  Reaction	  mechanism	  for	  JmjC-­‐domain	  containing	  histone	  
demethylases	   (modified	   from	  Ref.	   45)	   	   c,	   	   Inhibitors	   to	   LSD1.	   	   The	   general	  monooxidase	   inhibitor	  
tranylcypromine,	  and	  the	  derivative	  [trans-­‐N-­‐((2-­‐methoxypyridin-­‐3-­‐yl)methyl)-­‐2-­‐phenylcyclopropan-­‐
1-­‐amine)]	  developed	  by	  the	  biotech	  company	  Oryzon	  (Ref.	  63).	  	  d,	  	  LSD1	  is	  part	  of	  several	  different	  
chromatin	   complexes,	   including	   NuRD	   and	   CoREST,	   in	   which	   it	   catalyses	   the	   demethylation	   of	  
H3K4me2/me1,	   and	   as	   an	   associated	   protein	   with	   the	   androgen	   receptor,	   together	   with	   JMJD2	  
histone	   demethylases,	   where	   it	   is	   responsible	   for	   the	   demethylation	   of	   H3K9me2/me1	   (Refs.	  
102,103).	  
	  
Figure	   4	   Bromodomain	   proteins	   and	   inhibitors	   to	   these.	   	   a,	   The	   Bromodomain	   can	   bind	   to	  
acetylated	   lysines,	   which	   are	   associated	   with	   actively	   transcribed	   promoters.	   	   The	   bromodomain	  
proteins	  (here	  illustrated	  by	  BRD4)	  have	  a	  variety	  of	  functions,	  including	  mediating	  the	  initiation	  and	  
elongation	  of	  transcription.	  	  It	  interacts	  with	  p-­‐TEFb,	  which	  phosphorylates	  the	  C-­‐terminal	  domain	  of	  
of	  RNA	  polymerase	  II	  (Pol	  II)	  and	  induces	  transcriptional	  elongation.	  	  BRD4	  has	  also	  been	  described	  
to	   interact	  with	   a	   number	  of	   protein	   complexes	   involved	   in	   transcriptional	   regulation	  b,	   Chemical	  
structures	  of	  prototypical	  BET	  inhibitors.	  	  The	  compounds	  bind	  to	  all	  members	  of	  the	  BET	  sub-­‐family	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(Brd2,	   Brd3,	   Brd4	   and	   BrdT)	  with	   similar	   affinity	   and	   regulate	   the	   transcription	   of	   key	   oncogenes	  
including	  the	  MYC	  family	  and	  BCL2.	  
	  
BOX	  1.	  Post	  translation	  modifications	  of	  DNA	  and	  histones	  and	  their	  role	  in	  chromatin	  
organisation	  and	  gene	  expression.	  	  	  
DNA	   is	  wrapped	  around	  histones	   (H2A,	  H2B,	  H3	  and	  H4)	   to	   form	  nucleosomes.	   	  Nucleosomes	  are	  
further	  compacted	  to	   form	  condensed	  chromatin.	   	  The	  compaction	  of	  DNA	   is	   in	  part	  regulated	  via	  
posttranslational	  modifications	  (PTMs)	  of	  the	  histone	  tails,	  which	  are	  protruding	  from	  nucleosomes.	  	  
Epigenetic	  regulators	  can	  in	  popular	  terms	  be	  divided	  into	  writers,	  readers	  or	  erasers	  of	  PTMs.	  The	  
writers	  comprise	  enzymes	  such	  as	  histone	  acetylases,	  kinases,	  DNA	  and	  histone	  methyltransferases	  
and	  ubiquitin	   ligases.	   	   The	  writers	   catalyse	   the	  PTMs	   (the	   epigenetic	   imprints)	   on	   the	  DNA	  or	   the	  
proteins,	   and	   may	   impose	   epigenetic	   heritability	   such	   as	   DNA	   methylation	   through	   copying	   and	  
maintaining	   the	  modification.	  Other	  modifications,	   such	  as	  histone	  acetylation,	   respond	   rapidly	   to	  
environmental	   stimuli	   and	   they	   are	   therefore	   more	   dynamic.	   	   Readers	   of	   the	   post-­‐translational	  
modification	   include	   proteins	   with	   specific	   domains,	   such	   as	   Bromo-­‐,	   Chromo-­‐,	   Tudor-­‐,	   MBT-­‐,	  
PWWP-­‐,	  WD40-­‐	  and	  PHD-­‐domains,	  which	  bind	  to	  the	  specific	  modification.	  	  The	  readers,	  which	  are	  
often	  found	  in	  large	  protein	  complexes,	  interpret	  the	  modification	  and	  impose	  changes	  in	  chromatin	  
structure.	   	   The	   erasers,	   such	   as	   histone	  deacetylases	   (HDACs)	   and	  histone	  demethylases,	   serve	   to	  
erase	  the	  PTMs	  and	  prepare	  the	  histones	  for	  other	  modifications.	  	  
